Related Experiment Videos
Activation of platelets by eosinophil granule proteins
M S Rohrbach1, C L Wheatley, N R Slifman
1Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905.
The Journal of Experimental Medicine
|October 1, 1990
Summary
Eosinophil cationic proteins, major basic protein (MBP) and eosinophil peroxidase (EPO), act as potent platelet agonists. They trigger platelet secretion through a unique activation pathway, distinct from thrombin.
Area of Science:
- Hematology
- Immunology
- Cell Biology
Background:
- Eosinophils are key immune cells involved in inflammatory responses.
- Eosinophil granule proteins, including MBP and EPO, are released during inflammation.
- Platelets play crucial roles in hemostasis and immune modulation.
Purpose of the Study:
- To investigate the potential of eosinophil cationic proteins, specifically MBP and EPO, to activate platelets.
- To characterize the mechanism of platelet activation induced by MBP and EPO.
Main Methods:
- Experiments utilized unstirred platelet suspensions.
- Platelet secretion of 5-hydroxytryptamine, alpha granule, and lysosome components was measured.
- The effects of MBP and EPO were assessed in the presence of indomethacin and PGE1.
- Comparisons were made to thrombin-induced platelet activation.
Main Results:
- Both MBP and EPO induced a dose-dependent, nonlytic secretion of platelet 5-hydroxytryptamine.
- MBP also stimulated the release of platelet alpha granule and lysosome contents.
- PGE1 inhibited MBP and EPO-induced secretion, but differently than thrombin's inhibition.
- Indomethacin did not prevent MBP and EPO-mediated secretion.
Conclusions:
- MBP and EPO are identified as strong platelet agonists.
- These eosinophil proteins activate platelets via a distinct mechanism compared to thrombin.
- The findings suggest a novel role for eosinophil cationic proteins in platelet function and potentially in inflammatory processes.